<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="global pandemic. In December 2019, a novel coronavirus, the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in the"/>
 <result pre="pandemic. In December 2019, a novel coronavirus, the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), broke out in the Chinese"/>
 <result pre="In December 2019, a novel coronavirus, the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), broke out in the Chinese province"/>
 <result pre="of people worldwide. Infected patients mostly exhibit general signs of" exact="pneumonia" post="(fever, dyspnea, coughing and desaturation) and a presumably significant"/>
 <result pre="ventilation (Huang et al. 2020; Raoult et al. 2020). Typical" exact="acute" post="phase laboratory findings are present in admitted COVID-19 patients,"/>
 <result pre="2020). Retrospective analysis of the earlier-reported SARS-CoV, causing the ‘severe" exact="acute" post="respiratory syndrome (SARS)’ and also infecting humans via ACE2,"/>
 <result pre="Retrospective analysis of the earlier-reported SARS-CoV, causing the ‘severe acute" exact="respiratory" post="syndrome (SARS)’ and also infecting humans via ACE2, showed"/>
 <result pre="analysis of the earlier-reported SARS-CoV, causing the ‘severe acute respiratory" exact="syndrome" post="(SARS)’ and also infecting humans via ACE2, showed that"/>
 <result pre="(SARS)’ and also infecting humans via ACE2, showed that the" exact="disease" post="was accompanied by abnormal liver function which could be"/>
 <result pre="accompanied by abnormal liver function which could be due to" exact="viral" post="replication in the liver (Cui et al. 2004). It"/>
 <result pre="2006). It has been reported that patients suffering from certain" exact="viral" post="infections, such as infections caused by hepatitis C and"/>
 <result pre="reported that patients suffering from certain viral infections, such as" exact="infections" post="caused by hepatitis C and human immunodeficiency viruses, are"/>
 <result pre="suffering from certain viral infections, such as infections caused by" exact="hepatitis" post="C and human immunodeficiency viruses, are more prone for"/>
 <result pre="infections, such as infections caused by hepatitis C and human" exact="immunodeficiency" post="viruses, are more prone for developing drug-induced liver injury"/>
 <result pre="novel, potentially hepatotoxic, antiviral drugs and perhaps also antibiotics for" exact="bacterial" post="superinfections (Xu et al.2020a, b). Hydroxychloroquine is applied as"/>
 <result pre="antiviral drug, with sparse evidence in small clinical settings. Yet," exact="viral" post="replication and disease progression would be reduced and overall"/>
 <result pre="sparse evidence in small clinical settings. Yet, viral replication and" exact="disease" post="progression would be reduced and overall survival would increase."/>
 <result pre="tissue seems ambiguous, since it is used to treat liver" exact="infection" post="with protozoa (i.e. malaria) but cases of fulminant hepatic"/>
 <result pre="azithromycin initiation (Martinez et al. 2015). Patients suffering either from" exact="diabetes" post="type 1 or 2, or developing hypertension, often receive"/>
 <result pre="initiation (Martinez et al. 2015). Patients suffering either from diabetes" exact="type 1" post="or 2, or developing hypertension, often receive blood pressure"/>
 <result pre="often receive blood pressure reducing ACE inhibitors and angiotensin II" exact="type I" post="receptor blockers, which may lead to ACE2 overexpression. Therefore,"/>
 <result pre="2020; Fitzgerald 2020). Furthermore, these patients often suffer from the" exact="metabolic syndrome," post="which is a major risk factor for non-alcoholic fatty"/>
 <result pre="the metabolic syndrome, which is a major risk factor for" exact="non-alcoholic fatty liver" post="disease (NAFLD). NAFLD can sensitize the liver for hepatotoxicants"/>
 <result pre="metabolic syndrome, which is a major risk factor for non-alcoholic" exact="fatty liver disease" post="(NAFLD). NAFLD can sensitize the liver for hepatotoxicants such"/>
 <result pre="syndrome, which is a major risk factor for non-alcoholic fatty" exact="liver disease" post="(NAFLD). NAFLD can sensitize the liver for hepatotoxicants such"/>
 <result pre="which is a major risk factor for non-alcoholic fatty liver" exact="disease" post="(NAFLD). NAFLD can sensitize the liver for hepatotoxicants such"/>
 <result pre="a major risk factor for non-alcoholic fatty liver disease (NAFLD)." exact="NAFLD" post="can sensitize the liver for hepatotoxicants such as acetaminophen"/>
 <result pre="al. 2017), which is the advised and widely used anti-pyretic" exact="symptomatic" post="drug treatment. Although it is actually not known whether"/>
 <result pre="actually not known whether a link exists between COVID-19 and" exact="liver steatosis," post="it is worrying that in a recent post-mortem histopathological"/>
 <result pre="analysis of a liver biopsy of a COVID-19 patient microvesicular" exact="liver steatosis" post="was observed (Xu et al.2020a, b). Even though this"/>
 <result pre="that patients suffering from COVID-19 exhibited increased serum levels of" exact="monocyte" post="chemoattractant protein-1 (MCP-1) (Huang et al. 2020), which is"/>
 <result pre="in combined COVID-19 and DILI. Knowing that liver dysfunction and" exact="NAFLD" post="are more common in the elderly, who are also"/>
 <result pre="to evaluate hepatotoxic properties of (novel) drugs in a relatively" exact="short" post="time. This has been robustly demonstrated for a large"/>
 <result pre="al. 2016; Kuna et al. 2018). Also co-morbidities such as" exact="NAFLD" post="that increase the risk for developing DILI can be"/>
 <result pre="aspects of COVID-19 treatment. Overall, despite the indications that SARS-CoV-2" exact="infection" post="might have an influence on normal hepatic functions and"/>
 <result pre="that they have no conflict of interest. References References AdamsDHHubscherSGSystemic" exact="viral" post="infections and collateral damage in the liverAm J Pathol20061681057105910.2353/ajpath.2006.05129616565481"/>
 <result pre="they have no conflict of interest. References References AdamsDHHubscherSGSystemic viral" exact="infections" post="and collateral damage in the liverAm J Pathol20061681057105910.2353/ajpath.2006.05129616565481 BoeckmansJNataleABuylKet"/>
 <result pre="BonaciniMLiver injury during highly active antiretroviral therapy: the effect of" exact="hepatitis" post="C coinfectionClin Infect Dis20043810410810.1086/38145314679456 ChaiXHuLZhangYet al.Specific ACE2 expression in"/>
 <result pre="infectionbioRxiv202010.1101/2020.02.03.931766 ChenGWuDGuoWet al.Clinical and immunologic features in severe and moderate" exact="coronavirus disease" post="2019J Clin Invest202010.1172/JCI13724432250342 CuiHTongXLiPet al.Serum hepatic enzyme manifestations in"/>
 <result pre="ChenGWuDGuoWet al.Clinical and immunologic features in severe and moderate coronavirus" exact="disease" post="2019J Clin Invest202010.1172/JCI13724432250342 CuiHTongXLiPet al.Serum hepatic enzyme manifestations in"/>
 <result pre="Invest202010.1172/JCI13724432250342 CuiHTongXLiPet al.Serum hepatic enzyme manifestations in patients with severe" exact="acute" post="respiratory syndrome: retrospective analysisWorld J Gastroenterol2004101652165510.3748/wjg.v10.i11.165215162543 FangLKarakiulakisGRothMAre patients with"/>
 <result pre="CuiHTongXLiPet al.Serum hepatic enzyme manifestations in patients with severe acute" exact="respiratory" post="syndrome: retrospective analysisWorld J Gastroenterol2004101652165510.3748/wjg.v10.i11.165215162543 FangLKarakiulakisGRothMAre patients with hypertension"/>
 <result pre="acute respiratory syndrome: retrospective analysisWorld J Gastroenterol2004101652165510.3748/wjg.v10.i11.165215162543 FangLKarakiulakisGRothMAre patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
 <result pre="syndrome: retrospective analysisWorld J Gastroenterol2004101652165510.3748/wjg.v10.i11.165215162543 FangLKarakiulakisGRothMAre patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir Med202010.1016/S2213-2600(20)30116-832222169 FitzgeraldGAMisguided"/>
 <result pre="infection?Lancet Respir Med202010.1016/S2213-2600(20)30116-832222169 FitzgeraldGAMisguided drug advice for COVID-19Science2020367143410.1126/science.abb803432198292 GaoBTsukamotoHInflammation in" exact="alcoholic" post="and nonalcoholic fatty liver disease: friend or foe?Gastroenterology20161501704170910.1053/j.gastro.2016.01.02526826669 GautretPLagierJParolaPet"/>
 <result pre="FitzgeraldGAMisguided drug advice for COVID-19Science2020367143410.1126/science.abb803432198292 GaoBTsukamotoHInflammation in alcoholic and nonalcoholic" exact="fatty liver" post="disease: friend or foe?Gastroenterology20161501704170910.1053/j.gastro.2016.01.02526826669 GautretPLagierJParolaPet al.Hydroxychloroquine and azithromycin as"/>
 <result pre="non-randomized clinical trialInt J Antimicrob Agents202010.1016/j.ijantimicag.2020.1059497102549 GuanWNiZHuYet al.Clinical characteristics of" exact="coronavirus disease" post="2019 in ChinaN Engl J Med202010.1056/NEJMoa200203232220206 GurwitzDAngiotensin receptor blockers"/>
 <result pre="clinical trialInt J Antimicrob Agents202010.1016/j.ijantimicag.2020.1059497102549 GuanWNiZHuYet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med202010.1056/NEJMoa200203232220206 GurwitzDAngiotensin receptor blockers"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov202061610.1038/s41421-020-0156-032194981 LiuWTaoZWLeiWet al.Analysis of factors associated with"/>
 <result pre="infection in vitroCell Discov202061610.1038/s41421-020-0156-032194981 LiuWTaoZWLeiWet al.Analysis of factors associated with" exact="disease" post="outcomes in hospitalized patients with 2019 novel coronavirus diseaseChin"/>
 <result pre="novel coronavirus diseaseChin Med J (Engl)202010.1097/CM9.000000000000077532187045 MakinAJWendonJFittSet al.Fulminant hepatic failure" exact="secondary" post="to hydroxychloroquineGut19943556957010.1136/gut.35.4.5698175002 MartinezMAVuppalanchiRFontanaRJet al.Clinical and histologic features of azithromycin-induced"/>
 <result pre="features of azithromycin-induced liver injuryClin Gastroenterol Hepatol20151336937610.1016/j.cgh.2014.07.05425111234 MassartJBegricheKMoreauCet al.Role of" exact="nonalcoholic fatty liver disease" post="as risk factor for drug-induced hepatotoxicityJ Clin Transl Res.2017321223210.18053/jctres.03.2017S1.00628691103"/>
 <result pre="of azithromycin-induced liver injuryClin Gastroenterol Hepatol20151336937610.1016/j.cgh.2014.07.05425111234 MassartJBegricheKMoreauCet al.Role of nonalcoholic" exact="fatty liver disease" post="as risk factor for drug-induced hepatotoxicityJ Clin Transl Res.2017321223210.18053/jctres.03.2017S1.00628691103"/>
 <result pre="azithromycin-induced liver injuryClin Gastroenterol Hepatol20151336937610.1016/j.cgh.2014.07.05425111234 MassartJBegricheKMoreauCet al.Role of nonalcoholic fatty" exact="liver disease" post="as risk factor for drug-induced hepatotoxicityJ Clin Transl Res.2017321223210.18053/jctres.03.2017S1.00628691103"/>
 <result pre="liver injuryClin Gastroenterol Hepatol20151336937610.1016/j.cgh.2014.07.05425111234 MassartJBegricheKMoreauCet al.Role of nonalcoholic fatty liver" exact="disease" post="as risk factor for drug-induced hepatotoxicityJ Clin Transl Res.2017321223210.18053/jctres.03.2017S1.00628691103"/>
 <result pre="drug-induced hepatotoxicityJ Clin Transl Res.2017321223210.18053/jctres.03.2017S1.00628691103 MichautAMoreauCRobinMAet al.Acetaminophen-induced liver injury in" exact="obesity" post="and nonalcoholic fatty liver diseaseLiver Int20143417117910.1111/liv.1251424164713 NaidooKHassan-MoosaRMlotshwaPet al.High rates"/>
 <result pre="Transl Res.2017321223210.18053/jctres.03.2017S1.00628691103 MichautAMoreauCRobinMAet al.Acetaminophen-induced liver injury in obesity and nonalcoholic" exact="fatty liver" post="diseaseLiver Int20143417117910.1111/liv.1251424164713 NaidooKHassan-MoosaRMlotshwaPet al.High rates of drug-induced liver injury"/>
 <result pre="drug-induced liver injury in people living with HIV coinfected with" exact="tuberculosis" post="(TB) irrespective of antiretroviral therapy timing during antituberculosis treatment:"/>
 <result pre="coronavirus infectionsLiver Int202010.1111/liv.1443532187823 XuZShiLWangYet al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med202010.1016/S2213-2600(20)30076-X32109425 ZhangCShiLWangFLiver injury in COVID-19:"/>
 <result pre="infectionsLiver Int202010.1111/liv.1443532187823 XuZShiLWangYet al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med202010.1016/S2213-2600(20)30076-X32109425 ZhangCShiLWangFLiver injury in COVID-19: management"/>
 <result pre="Hepatol202010.1016/S2468-1253(20)30057-132192627 ZhouFYuTDuRet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
</results>
